Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
This study is ongoing, but not recruiting participants.
Study NCT00422799   Information provided by Dana-Farber Cancer Institute

First Received on January 12, 2007.   Last Updated on December 5, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Waldenstrom's Macroglobulinemia
Additional conditions recognized in this trial
Waldenstrom Macroglobulinemia
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Plasma Cell
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Bortezomib
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Enzyme Inhibitors
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services